RoslinCT

Edinburgh, UK · Hopkinton, MA
CAR-T Cell Therapy
Program data pending ClinicalTrials.gov matching · Last scored 2026-03-15
80.4
Signal Score
✓ FDA Inspections (1) ○ Clinical Trials ○ SEC Filings ✓ Press (3)

Quick Facts: RoslinCT

Signal Score
80.4/100 (as of 2026-03-15)
Quality Compliance
100.0/100
Headquarters
Edinburgh, UK · Hopkinton, MA
Modalities
CAR-T, Cell Therapy
Active CGT Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance 100.0
FDA Inspections1 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2025-01-21)
Operations 79.3
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Source: ClinicalTrials.gov
No clinical trial matches found for this manufacturer · Operational score requires ClinicalTrials.gov data
Programs — no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 68.0
2 CGT manufacturing sites
Broad modality coverage (4 modalities)
Sites: Edinburgh, UK, Hopkinton, MA
Source: SEC EDGAR, press monitoring, company profiles
2 CGT manufacturing sites
StatusAvailable
2 CGT manufacturing sites
Broad modality coverage (4 modalities)
Sites: Edinburgh, UK, Hopkinton, MA
Recent Press3 articles
2 CGT manufacturing sites
Broad modality coverage (4 modalities)

FDA Inspection History

2025-01
NAI VAI OAI
Date Site Type Observations Classification
2025-01-21 Edinburgh Human Cellular, Tissue, and Gene Therapies Yes Voluntary Action Indicated (VAI)
Source: FDA Data Dashboard · Retrieved Mar 20, 2026

Recent News 3 articles

general 2026-03-19
Commercializing Autologous Cell Therapy: Bridging Clinical and Large-Scale Manufacturing - Genetic Engineering and Biotechnology News
Commercializing Autologous Cell Therapy: Bridging Clinical and Large-Scale Manufacturing  Genetic Engineering and Biotechnology News
Source →
general 2026-02-09
Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering - BioInformant
Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering  BioInformant
Source →
general 2026-02-01
Strategies for the Future of CAR-T Therapy Development in 2026 and Beyond - BioInformant
Strategies for the Future of CAR-T Therapy Development in 2026 and Beyond  BioInformant
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs →